Gilead Sciences Change in AR decreased by 140.2% to -$134.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 69.6%, from -$79.00M to -$134.00M. This is a positive signal — lower values indicate better performance for this metric.
A significant increase may signal aggressive revenue recognition or collection issues, while a decrease suggests improved cash conversion cycles.
The net change in the balance of accounts receivable during the reporting period, representing the difference between cr...
Should track closely with revenue growth; significant deviations from revenue trends warrant investigation.
anet_change_in_accounts_receivable| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$41.00M | -$699.00M | $452.00M | $372.00M | $281.00M | -$635.00M | $612.00M | -$220.00M | $66.00M | $29.00M | -$162.00M | -$72.00M | -$79.00M | $292.00M | $333.00M | -$134.00M |
| QoQ Change | — | <-999% | +164.7% | -17.7% | -24.5% | -326.0% | +196.4% | -135.9% | +130.0% | -56.1% | -658.6% | +55.6% | -9.7% | +469.6% | +14.0% | -140.2% |
| YoY Change | — | — | — | — | +785.4% | +9.2% | +64.5% | -178.3% | +110.4% | — | -126.5% | +67.3% | -219.7% | +906.9% | +305.6% | -69.6% |